Amendments to the Specification:

Please replace paragraphs **[0020]**, **[0039]** and **[0067]** with the following amended paragraphs:

[0020] An ~~alkaline~~ alkali metal salt, alkaline-earth metal salt, ammonium salt, iron salt or aluminium salt of the active substance may be used with equal preference as the active-substance salt; particularly preferably an ~~alkaline~~ alkali metal salt, most particularly preferably the sodium or potassium salt of the active substance may be present.

[0039] The coating dispersion or solution from which the gastric juice-resistant coating is applied, may have one of the ~~above-name~~ above-named softeners in addition to the corresponding polymers. Furthermore, the retarding coating materials listed above may also be applied, as a protective coating against the gastric acids, in various thicknesses, which are known to a person skilled in the art.

[0067] The dosage forms according to the invention were tested in the European Pharmacopoeia basket apparatus at a temperature of the released medium of 37 ± 0.5°C, and at a rate of 50 rpm for 2 hours in 600 ml synthetic gastric juices without enzymes at pH 1.2. Following this, the dosage form was tested for a further 8 hours in 900 ml synthetic intestinal juices without enzymes at pH 7.2. The quantity of active substance released at a given time was determined in each case by means of HPLC. The values shown are average values based in each case on 3 samples. The invention will be explained below with reference to examples. The explanations are merely exemplary and do not ~~restricted~~ restrict the general idea of the invention.